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 Learning Signals of Adverse Drug-Drug Interactions                                               
from the Unstructured Text of Electronic Health Records 
Srinivasan V Iyer, Paea LePendu, Rave Harpaz, Anna Bauer-Mehren, Nigam H Shah 
Stanford University, Stanford, CA 
Abstract 
Drug-drug interactions (DDI) account for 30% of all adverse drug reactions, which are the fourth leading cause of 
death in the US. Current methods for post marketing surveillance primarily use spontaneous reporting systems for 
learning DDI signals and validate their signals using the structured portions of Electronic Health Records (EHRs). 
We demonstrate a fast, annotation-based approach, which uses standard odds ratios for identifying signals of DDIs 
from the textual portion of EHRs directly and which, to our knowledge, is the first effort of its kind. We developed a 
gold standard of 1,120 DDIs spanning 14 adverse events and 1,164 drugs. Our evaluations on this gold standard 
using millions of clinical notes from the Stanford Hospital confirm that identifying DDI signals from clinical text is 
feasible (AUROC=81.5%). We conclude that the text in EHRs contain valuable information for learning DDI 
signals and has enormous utility in drug surveillance and clinical decision support. 
Introduction 
Electronic Health Record (EHR) systems are becoming highly prevalent today and have the potential1 to add to the 
success of spontaneous reporting systems for post marketing surveillance of drugs, especially to identify risky drug 
interactions. Although most EHR based drug safety research relies on coded information, studies have established 
several advantages to using the clinical text. In this work, we apply data mining methods on the textual portion of 
EHRs to learn drug-drug interaction (DDI) signals, which, to our knowledge is the first study of its kind. 
Methods 
We use an ontology-based text processing workflow to tag a corpus of 9,078,736 time-stamped textual notes from 
the Stanford Hospital (STRIDE) with drug and disease concepts (1,164 drugs and 14 events) and create a concept 
timeline for each patient. We check for a drug-drug-event interaction signal, by comparing the odds of the event 
among patients on both drugs to that in patients on at most one of the drugs. We adjust the odds ratio for 
confounding by age, gender, race, drug count, disease count and note count. Finally, we build a gold standard of 560 
known interactions and an equal number of random unknown interactions and use it to validate our method. 
Results 
Our method achieves an area under the Receiver 
Operator Characteristic curve of 81.5% on the 
gold standard, with a sensitivity of 37.98% at a 
specificity of 96.56% and a positive predictive 
value of 91.71%. We also calculate the prevalence 
of the event among patients on drug combinations 
representing true interactions (Table 1), and argue 
that such prevalence information can be a unique 
resource to prioritize known interactions.  
Discussion 
Our work shows the feasibility of the use of EHR 
text to generate hypotheses about DDIs and to 
examine their real world prevalence, which could 
serve as an important step forward for Phase IV 
drug surveillance and meaningful use of EHRs. Having longitudinal coverage and being minimally affected by 
reporting and publicity bias, makes the prevalence information generated from EHRs extremely useful for 
Computerized Physician Order Entry (CPOE) systems to tackle the problem of alert fatigue; and in choosing 
combination therapy from among many drug combinations.  Confounding, accuracy of concept recognition, 
detection of the drug interaction period and other limitations of this method will be addressed in future work. 
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Table 1. The drug combinations with the highest event prevalence in 
STRIDE, for each event. (Prev = #(Exposed and affected)/#(Exposed)) 
Adverse	  Event	  (#Patients)	   Drug1	   Drug2	   a	   b	   Prev.	  
	  	  (%)	  
Parkinsonian	  Symptoms	  (3541)	   levodopa	   lorazepam	   176	   235	   42.82	  
Cardiac	  Arrhythmias	  (88555)	   potassium	  chloride	   lisinopril	   1091	   1615	   40.32	  
Neutropenia	  (14322)	   paclitaxel	   trastuzumab	   140	   567	   19.8	  
Bradycardia	  (22906)	   amiodarone	   metoprolol	   796	   3671	   17.82	  
Hypoglycemia	  (11150)	   glipizide	   lisinopril	   367	   2160	   14.52	  
Acute	  Renal	  Failure	  (32197)	   hydrochlorothiazide	   ibuprofen	   884	   8375	   9.55	  
Hyperkalemia	  (4973)	   potassium	  chloride	   spironolactone	   349	   3471	   9.14	  
Hyperglycemia	  (19189)	   prednisone	   salmeterol	   379	   4612	   7.59	  
Nephrotoxicity	  (1460)	   fluconazole	   tacrolimus	   85	   1208	   6.57	  
Pancytopenia	  (8718)	   mercaptopurine	   azathioprine	   15	   278	   5.12	  
Hypokalemia	  (8405)	   prednisone	   salmeterol	   222	   4982	   4.27	  
Serotonin	  Syndrome	  (674)	   tramadol	   duloxetine	   57	   1301	   4.2	  
QT	  prolongation	  (1260)	   amiodarone	   ciprofloxacin	   46	   2487	   1.82	  
Rhabdomyolysis	  (1378)	   ciprofloxacin	   simvastatin	   50	   5184	   0.96	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